Literature DB >> 21895620

Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study.

C-F Kuo1, L-C See, K-H Yu, I-J Chou, H-C Chang, M-J Chiou, S-F Luo.   

Abstract

BACKGROUND: Nationwide data on the epidemiology of dermatomyositis (DM) and polymyositis (PM) were limited.
OBJECTIVES: This study was to estimate the incidence, occurrence of cancer and mortality of DM and PM in Taiwan.
METHODS: Both the register of critical illness of the Taiwan National Health Insurance Research Dataset and the National Death Registry of Taiwan were used to calculate estimates of the incidence, cancer association, and mortality of DM and PM between 2003 and 2007.
RESULTS: A total of 803 DM and 500 PM cases were identified between 2003 and 2007. Mean age at diagnosis was 44·0 ± 18·3 years for DM and 49·2 ± 15·9 years for PM. The overall annual incidences of DM and PM were 7·1 (95% CI 6·6-7·6) and 4·4 (95% CI 4·0-4·8) cases per million population. The incidence of both DM and PM increased with age and reached a peak at age 50-59 years. One hundred and eleven (13·8%) patients with DM and 31 (6·2%) patients with PM had cancers. The diagnosis of most cancers was made after the diagnoses of DM (n = 71; 64·0%) and PM (n = 21; 67·7%). Overall, the standardized incidence ratios (SIR) for cancer were 5·36 (4·12-6·87) and 1·80 (1·10-2·79) among patients with DM and PM; however, during the first year, SIRs for cancer were 24·55 (95% CI 18·62-31·79) and 9·17 (95% CI 14·82-15·93) in patients with DM and PM, respectively. The most common types of cancer were nasopharyngeal cancer for men and breast cancer for women. Patients with DM and PM had standardized mortality ratios of 7·68 (6·41-9·01) and 5·29 (4·28-6·48).
CONCLUSION: This study reports robust estimates of important aspects of the epidemiology of both DM and PM in Taiwan. This highlights the rarity of these diseases, and their associated cancer risks and increased mortality.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.

Entities:  

Mesh:

Year:  2011        PMID: 21895620     DOI: 10.1111/j.1365-2133.2011.10595.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  32 in total

1.  Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.

Authors:  Hai-Long Wang; Yong-Ming Zhou; Guang-Zhao Zhu; Zhu Yang; Bao-Jin Hua
Journal:  Clin Rheumatol       Date:  2017-05-16       Impact factor: 2.980

2.  Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study.

Authors:  Kyoko Motomura; Hiroyuki Yamashita; Saeko Yamada; Yuko Takahashi; Hiroshi Kaneko
Journal:  Rheumatol Int       Date:  2019-08-23       Impact factor: 2.631

3.  Sex differential association of dermatomyositis with Sjögren syndrome.

Authors:  Chia-Chun Tseng; Shun-Jen Chang; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Ming-Chia Hsieh; Jeng-Hsien Yen
Journal:  CMAJ       Date:  2017-02-06       Impact factor: 8.262

Review 4.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Authors:  Adam M Huber; Gulnara Mamyrova; Peter A Lachenbruch; Julia A Lee; James D Katz; Ira N Targoff; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-05       Impact factor: 4.794

Review 6.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

7.  Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.

Authors:  Nicholas E Johnson; W David Arnold; Donald Hebert; Kelly Gwathmey; Mazen M Dimachkie; Richard J Barohn; April L McVey; Mamatha Pasnoor; Anthony A Amato; Michael P McDermott; John Kissel; Chad R Heatwole
Journal:  Neuromuscul Disord       Date:  2015-05-07       Impact factor: 4.296

8.  Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.

Authors:  Yunyoung C Chang; Victoria P Werth
Journal:  Curr Dermatol Rep       Date:  2013-01-24

9.  High- density lipoprotein function is abnormal in idiopathic inflammatory myopathies.

Authors:  Sangmae Sharon Bae; Yuen Yin Lee; Ani Shahbazian; Jennifer Wang; David Meriwether; Ilana Golub; Buzand Oganesian; Tyler Dowd; Srinivasa T Reddy; Christina Charles-Schoeman
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

Review 10.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.